UNSPSC 51282511: Cefazolin or cefazoline or cephazolin

This classification denotes a cephalosporin antibiotic with the molecular formula C14H14N8O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHS69L0Y4T, chemically known as 7-(1-(1h-)-tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid but generally known as cefazolin, which bears US NIH Compound Identifier 33255. European Medicines Agency schedules Cefazolin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07379MIG.

UNSPSC 51282511 Cefazolin or cefazoline or cephazolin is a Commodity code that captures pharmaceutical products, though recent state and local activity shows that the code is being applied inconsistently — the most recent tagged opportunities involve Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone rather than cefazolin-class antibiotics. State and local buyers soliciting under this code include state health departments and county health authorities. The Illinois Department of Public Health and Seminole County, Florida both appear in recent records, though the actual pharmaceutical products being procured do not align with the code's nominal scope of cefazolin products.

Activity is limited and geographically scattered. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over 12 months with two renewal options; that award closed on September 11, 2026. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023, per the source date) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though this procurement also does not represent cefazolin products. The mismatch between code assignment and actual procured products suggests the code may see limited relevant activity, or state and local offices are applying it to general-category pharmaceutical acquisitions beyond its specific scope.